Cary Posted December 13, 2003 Share Posted December 13, 2003 Drug Week, Dec 19, 2003 p169 COX-2 and tumor angiogenesis correlate in non-small cell lung cancers. Full Text: COPYRIGHT 2003 NewsRX 2003 DEC 19 - (NewsRx.com & NewsRx.net) -- COX-2 and tumor angiogenesis correlate in non-small cell lung cancers. "The role of cyclooxygenase (COX)-2 expression and angiogenesis of lung cancer is yet to be delineated. Eighty four non-small cell lung cancer (NSCLC) specimens were evaluated for COX-2 expression, microvessel density (MVD), and vascular endothelial growth factor (VEGF) expression by immunohistochemical methods. The relationships between COX-2 expression and MVD, VEGF expression, and survival time were analyzed," scientists writing in the journal Lung Cancer report. "COX-2 expression was observed in the cytoplasm and membrane of the carcinoma cells and premalignant cells. COX-2 was positive in 67 cases (79.8%). There was a statistically significant correlation between COX-2 expression and tumor size, TNM stage, tumor type, VEGF expression, and vascular pattern with survival in univariate analysis. No significant correlation was seen between COX-2, VEGF expression and MVD," noted H.S. Kim and colleagues, Chonnam National University, School of Medicine. "A lack of expression of either COX-2 or VEGF expression or both, however, was associated with lower MVD than the group with both expressed. The difference was statistically significant (p=0.005). Statistically significant differences were also observed according to TNM stage, vascular pattern, COX-2 expression, and VEGF expression." "With multivariate analysis, only TNM stage and COX-2 expression retained their significance as independent predictors of survival. COX-2 expression takes part in tumor angiogenesis and is a significant poor prognostic factor in the surgically resected NSCLC. COX-2 inhibitor, either in combination therapy with other agents, or for chemoprevention, may be effective via suppression of angiogenesis in this fatal disease," researchers concluded. Kim and colleagues published their study in Lung Cancer (Correlation between cyclooxygenase-2 and tumor angiogenesis in non-small cell lung cancer. Lung Cancer, 2003;42(2):163-170). Additional information can be obtained by contacting C.S. Park, Chonnam National University, School of Medicine, Department Pathology, 5 Hak Dong, Gwangju 501190, South Korea. The publisher of the journal Lung Cancer can be contacted at: Elsevier Science Ireland Ltd., Customer Relations Manager, Bay 15, Shannon Industrial Estate CO, Clare, Ireland. The information in this article comes under the major subject areas of Angiogenesis, Enzymology, Oncology, and Lung Cancer. This article was prepared by Drug Week editors from staff and other reports. Quote Link to comment Share on other sites More sharing options...
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.